IMNM
Immunome, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.76
−1.47%Jul 20, 2026, 11:30 UTC
Immunome dosed the first patient in a Phase 1 trial of IM-3050, an FAP-targeted radioligand therapy, for advanced solid tumors.
Source:Jul 8, 2026, 11:30 UTC
Immunome announced that the U.S. FDA accepted its New Drug Application for varegacestat for the treatment of adults with desmoid tumors.